Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis

Glen S. Hazlewood, Samuel L. Whittle, Mohammed Mujaab Kamso, Elie A. Akl, George A. Wells, Peter Tugwell, Megan Thomas, Chloe Lee, Maede Ejaredar, Daksh Choudhary, Dennis Ryan Neuen, Julia New-Tolley, Maria Powell, Alannah Quinlivan, Amro Qaddoura, Rob Deardon, Lara J. Maxwell, Jordi Pardo Pardo, Shannon Kelly, Rachelle Buchbinder

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. The primary objective is to compare the benefits and harms of different disease-modifying anti-rheumatic drugs (DMARDs) as initial therapy and after failure of conventional synthetic DMARDs or biologic or targeted synthetic DMARDs in adults with rheumatoid arthritis through a network meta-analysis (NMA). A secondary objective is to rank the interventions for both benefits and harms. This protocol describes the approach for separate NMAs for the three populations of interest (described below), which we intend to publish as three separate Cochrane Reviews. 1) Disease-modifying anti-rheumatic drugs for rheumatoid arthritis as initial therapy: a systematic review and network meta-analysis. 2) Disease-modifying anti-rheumatic drugs for rheumatoid arthritis after failure of conventional synthetic disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. 3) Disease-modifying anti-rheumatic drugs for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Original languageEnglish
Article numberCD013562
Number of pages21
JournalCochrane Database of Systematic Reviews
Volume2020
Issue number3
DOIs
Publication statusPublished - 22 Mar 2020

Cite this